Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil

Table 4 The incidence of grade 3 or 4 side effects in patients with UGC with SMI^High and SMI^Low

	SMI^High (n = 41)	SMI^Low (n = 42)	P value
All side effects of grade 3 or 4			0.028
Positive	10 (24.3)	20 (47.6)
Negative	31 (75.7)	22 (52.4)
Neutropenia of grade 3 or 4			0.421
Positive	6 (14.6)	9 (21.4)
Negative	35 (85.4)	33 (78.6)
Anemia of grade 3 or 4			0.309
Positive	1 (2.4)	0
Negative	40 (97.6)	42
Thrombocytopenia of grade 3 or 4			0.081
Positive	0	3 (7.1)
Negative	41	39 (92.9)
Gastrointestinal toxicity			0.039
Positive	3 (7.3)	10 (23.8)
Negative	38 (92.7)	32 (76.2)
FN			0.980
Positive	2 (4.9)	2 (4.8)
Negative	39 (95.1)	40 (95.2)

Data are presented as number (percentage) of patients
FN, febrile neutropenia; SMI^High, high skeletal muscle mass; SMI^Low, low skeletal muscle mass; UGC, unresectable gastric cancer; SMI, skeletal muscle mass

ISSN: 1471-2407